about-full-v3
About 340B Orphan Drug Solutions

You already spent the money.Let's go get it back.

340B Orphan Drug Solutions is a specialized buy-side recovery practice — and only that. I work exclusively with the four facility types the 2015 PhRMA v. HHS ruling made eligible for orphan drug pricing: Sole Community Hospitals (SCH), Critical Access Hospitals (CAH), Rural Referral Centers (RRC), and Free-Standing Cancer Centers (CAN). Twelve years. One lane. Every dollar recovered is a dollar you already paid out.

Dr. Lisa Nezneski, PharmD, BCPS
12 YearsOrphan drugs only. Nothing else.
100%Findings rate. Every engagement.
$200K+Average annual recovery, per facility.
< 1 QtrTypical time to first dollars back.

Here is how it actually goes

Most hospitals do not have an orphan drug problem they can see. That is precisely the problem.

Overwhelmed pharmacist BeforeWhere you are now
Your 340B program runs. Your pharmacy team is capable. Purchasing looks clean on the report. And every quarter, orphan drug dollars you are entitled to walk quietly out the door — because the drugs are priced at manufacturer discretion, the pricing moves constantly, split-billing software cannot keep pace, and no one on your staff has the hours to chase it. You do not see the loss, because nothing on your screen says "loss."
Team analyzing data What we doThe 4V Analysis
I run the 4V Analysis on your actual purchasing data. Visibility first: I show you what your orphan drug program is really doing, drug by drug. Then Verify: I isolate the specific purchases where you overpaid. Then Value: I put a hard dollar figure in the gap between what you were charged and what was available to you. Then Velocity: I execute the recovery — manufacturer outreach, pricing corrections, invoice adjustments, split-billing integration — and I keep the program running with quarterly updates and monthly alerts on newly approved drugs.
Pharmacist satisfied with results OutcomeWhat you keep
Money comes back. In a recent single engagement, a rural Critical Access Hospital in Minnesota recovered $247,000 — and the engagement paid for itself inside the first quarter. One Rural Referral Center recovered $4 million in a single quarter. Most facilities land north of $200,000 a year, every year. Your pharmacy team gets its time back, your CFO gets a number, and your orphan drug portfolio stops being a mystery and starts being an asset.

The 4V Analysis

This is the engine underneath every engagement, and it is the reason the findings rate has never broken. It works in under ten minutes as a first read, and in full depth as a recovery.

Visibility

I show you what your orphan drug program is genuinely doing right now — not what the report says it is doing.

Verify

I isolate the specific purchases where you were charged more than you had to pay, and I prove it line by line.

Value

I put a hard number in the gap between your data and your recoverable dollars, so your CFO has a figure and not a feeling.

Velocity

I execute — and the recovery lands fast. Most facilities see their first dollars back inside a single quarter.

Four ways to work together

Every engagement starts by finding your number. Where it goes from there is your call.

1 · Turn-Key Orphan Drug Buy-Side Recovery

For hospitals and health systems ready to recover now

Done for you, end to end. I identify the overpaid purchases, quantify what is recoverable, and execute the recovery through to realized dollars — hands-on and sustained, compounding quarter over quarter.

What's in it for you: found money, without adding a single hour to your team's week.

2 · Orphan Drug Recovery Opportunity Assessment

For health systems that want the number before they commit

A one-time, fixed-scope diagnostic that quantifies your recoverable orphan drug dollars and shows exactly where they live in your purchasing, broken out across every eligible facility in your system.

What's in it for you: you walk away with a hard figure and a roadmap — and the fee credits in full toward recovery work if you proceed.

3 · Fractional Orphan Drug Recovery

For GPOs, networks, and industry partners

Senior orphan drug capability embedded across your member or partner network — a PharmD specialist, never a junior analyst. Start with a pilot cohort, prove it, scale.

What's in it for you: a found-money benefit you can brand, own, and hand your members.

4 · On-Site Training

For hospital and partner teams building the muscle in-house

Tailored, in-person sessions that teach your pharmacy purchasing and finance teams to recognize, quantify, and capture orphan drug overpayments themselves.

What's in it for you: the framework stays with your team long after I leave.

What this is worth to you

  • Dollars you already spent, returned to your bottom line — an average of $200,000+ per facility, per year.
  • A customized orphan drug portfolio built around your actual case mix, not a generic list someone else is also using.
  • Quarterly updates and monthly alerts on newly approved drugs, so the program stays current without your team chasing it.
  • Split-billing integration, credit-and-rebill review, biosimilar selection strategy, and job aids your pharmacy team can actually use.
  • Your team's hours back. Recovery work is my job, not one more thing on their list.

"If your hospital has never had a dedicated orphan drug revenue review, you are almost certainly under-recovering. The only question is by how much."

Dr. Lisa Nezneski — Dr. Lisa Nezneski, PharmD, BCPS · Founder

Let's find your number

A 30-minute conversation is enough to tell whether there is money on your table. There almost always is.

Schedule a Call

Dr. Lisa Nezneski, PharmD, BCPS · Founder, 340B Orphan Drug Solutions
[email protected]

ABOUT US

GET TO KNOW US BETTER

At 340B Orphan Drug Solutions, we believe in the transformative power of having a turnkey system to manage Orphan Drugs in Expansion Entities. Our mission is simple: to empower Expansion Entities with strategic solutions that not only capture Orphan Drug savings, but also provide a customized Orphan Drug portfolio for your facility with less manual work that drives tangible growth and success. What sets us apart is not just our expertise but our commitment to understanding the unique DNA of each entity. It’s not just a list. It’s a partnership.

I'm Dr. Lisa Nezneski PharmD, BCPS

Dr. Lisa Nezneski developed and refined the Orphan Drug Support Program while serving as a Consultant. Her consulting career spans over three decades, serving small rural hospitals to university teaching hospitals. Well versed in the ever changing Orphan Drug Universe, she brings a wealth of experience to each client to individualize, understand, and solve Orphan Drug Issues. She is dedicated to bringing a heart-centered approach to each client.

WHAT WE BELIEVE

ABOUT OUR VISION AND MISSION

VISION

Our vision is to be the catalyst for transformative 340B Orphan Drug solutions that redefine industry standards. We envision a future where Expansion Entities not only capture outpatient savings, but also allow for the growth in Specialty, Contract, and Infusion Pharmacies.

MISSION

Our mission is to deliver strategic and impactful 340B Orphan Drug solutions that propel Expansion Entities to new heights of success. We are committed to leveraging our expertise in data-driven insights, customizing all aspects of Orphan Drug Management, and ​reducing the time and effort each facility has to invest.

Let's identify the 340B orphan drug savings your hospital is missing and put them back in your budget

© 2026 340B Orphan Drug Solutions. All rights reserved.